<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Ophthalmol</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">2168-6165</issn><issn pub-type="epub">2168-6173</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12232258</article-id><article-id pub-id-type="pmcid-ver">PMC12232258.1</article-id><article-id pub-id-type="pmcaid">12232258</article-id><article-id pub-id-type="pmcaiid">12232258</article-id><article-id pub-id-type="pmid">40608320</article-id><article-id pub-id-type="doi">10.1001/jamaophthalmol.2025.1851</article-id><article-id pub-id-type="publisher-id">eoi250031</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Long-Term Cannabis Use and Risk of Postoperative Proliferative Vitreoretinopathy</article-title><alt-title alt-title-type="headline">Cannabis Use and Proliferative Vitreoretinopathy</alt-title><alt-title alt-title-type="running-head">Cannabis Use and Proliferative Vitreoretinopathy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Alshaikhsalama</surname><given-names initials="AM">Ahmed M.</given-names></name><degrees>MD</degrees><xref rid="eoi250031aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alsoudi</surname><given-names initials="AF">Amer F.</given-names></name><degrees>MD</degrees><xref rid="eoi250031aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mukhtar</surname><given-names initials="A">Ali</given-names></name><degrees>MD</degrees><xref rid="eoi250031aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wai</surname><given-names initials="K">Karen</given-names></name><degrees>MD</degrees><xref rid="eoi250031aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Koo</surname><given-names initials="E">Euna</given-names></name><degrees>MD</degrees><xref rid="eoi250031aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kossler</surname><given-names initials="A">Andrea</given-names></name><degrees>MD</degrees><xref rid="eoi250031aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ludwig</surname><given-names initials="C">Chase</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="eoi250031aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mruthyunjaya</surname><given-names initials="P">Prithvi</given-names></name><degrees>MD</degrees><degrees>MHS</degrees><xref rid="eoi250031aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Rahimy</surname><given-names initials="E">Ehsan</given-names></name><degrees>MD</degrees><xref rid="eoi250031aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="eoi250031aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="eoi250031aff1"><label>1</label>Department of Ophthalmology, UT Southwestern Medical Center, Dallas, Texas</aff><aff id="eoi250031aff2"><label>2</label>Department of Ophthalmology, Baylor College of Medicine, Houston, Texas</aff><aff id="eoi250031aff3"><label>3</label>Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California</aff><aff id="eoi250031aff4"><label>4</label>Department of Ophthalmology, Palo Alto Medical Foundation, Palo Alto, California</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> April 20, 2025.</p><p content-type="published-online"><bold>Published Online:</bold> July 3, 2025. doi:<uri content-type="doi">10.1001/jamaophthalmol.2025.1851</uri></p><corresp id="eoi250031cor1"><bold>Corresponding Author:</bold> Ehsan Rahimy, MD, Department of Ophthalmology, Byers Eye Institute at Stanford University, 2452 Watson Court Palo Alto, CA 94303 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="rahimye@stanford.edu">rahimye@stanford.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Rahimy had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Alshaikhsalama, Alsoudi, Mukhtar, Wai, Ludwig, Rahimy.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Alshaikhsalama, Alsoudi, Mukhtar, Koo, Kossler, Mruthyunjaya, Rahimy.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Alshaikhsalama, Alsoudi, Rahimy.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> All authors.</p><p><italic toggle="yes">Statistical analysis:</italic> Alshaikhsalama, Alsoudi, Rahimy.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Mruthyunjaya, Rahimy.</p><p><italic toggle="yes">Supervision:</italic> Alshaikhsalama, Alsoudi, Koo, Kossler, Ludwig, Mruthyunjaya, Rahimy.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Koo reported consultant fees from Verana Health. Dr Mruthyunjaya reported grant support from Genentech; consultant fees from Aura Biosciences, Castle Biosciences, Alcon, Amgen, Immunogen, and Genentech; and being a lecturer for the Alcon Meeting. Dr Rahimy reported consultant and/or speaker fees from Alcon, Allergan/AbbVie, Apellis Pharmaceuticals, EyePoint Pharmaceuticals, Genentech, Harrow, Iveric Bio, Neurotech, Regeneron, and Zeiss outside the submitted work. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by a P30 Vision Research Core Grant from the National Eye Institute (P30-EY026877) and a grant from Research to Prevent Blindness. Additionally, this work was supported by a National Eye Institute K23 grant (K23EY035741) and E. Matilda Ziegler Foundation for the Blind (Dr Ludwig).</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-EOI250031-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-07-03T10:00"><day>3</day><month>7</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">492247</issue-id><elocation-id>e251851</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>07</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-08 10:25:49.607"><day>08</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamaophthalmol-e251851.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamaophthalmol-e251851.pdf">jamaophthalmol-e251851.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archopht/fullarticle/10.1001/jamaophthalmol.2025.1851"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" journal-id="JAMA Ophthalmol" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="40608332"><article-title>Cannabis Use and Proliferative Vitreoretinopathy Risk Reduction.</article-title><date><day>3</day><month>7</month><year>2025</year></date><source>JAMA Ophthalmol</source><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2025.1977</pub-id><pub-id pub-id-type="pmid">40608332</pub-id></related-article><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study examines data for patients with and without a history of cannabis use who underwent retinal detachment repair to assess the risk of developing proliferative vitreoretinopathy afterward.</p></abstract><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-eoi250031-1"><title>Question</title><p>Is cannabis use associated with proliferative vitreoretinopathy (PVR) development after initial retinal detachment (RD) repair?</p></sec><sec id="ab-eoi250031-2"><title>Findings</title><p>This cohort study examining data for 1193 matched patients found that those who underwent initial RD repair with concomitant cannabis use had a moderately lower risk of PVR development compared with patients without a history of cannabis use.</p></sec><sec id="ab-eoi250031-3"><title>Meaning</title><p>While this protective association noted with cannabis use could be due to the population using it rather than an effect of the cannabis itself, the findings suggest that cannabis might have a role in reducing PVR development; intervention trials would be needed to try to control for confounding factors.</p></sec></abstract><abstract><sec id="ab-eoi250031-4"><title>Importance</title><p>Proliferative vitreoretinopathy (PVR) is a major cause of retinal detachment (RD) repair failure, resulting in poor visual outcomes. Cannabis use continues to increase globally and may affect PVR development through its anti-inflammatory and neuroprotective properties, although this association remains unclear.</p></sec><sec id="ab-eoi250031-5"><title>Objective</title><p>To assess the risk of developing PVR among patients with concomitant cannabis use who underwent primary RD repair.</p></sec><sec id="ab-eoi250031-6"><title>Design, Setting, and Participants</title><p>This retrospective cohort study examined data from electronic health records for a multicenter research network extracted for the period February 1, 2005, to February 1, 2025. Participants were patients who underwent initial RD repair with pars plana vitrectomy (PPV) with or without scleral buckle (SB), primary SB, or pneumatic retinopexy. The records were used to identify patients diagnosed with concomitant cannabis-related disorder together with confirmatory testing of cannabis in urine or blood compared with a control group without documented use. Exclusion criteria were a history proliferative diabetic retinopathy or less than 6 months of follow-up.</p></sec><sec id="ab-eoi250031-7"><title>Exposures</title><p>Primary RD repair and cannabis-related disorder.</p></sec><sec id="ab-eoi250031-8"><title>Main Outcome Measures</title><p>Relative risk (RR) of developing PVR and requiring a subsequent complex RD repair at 6 months and 1 year of follow-up.</p></sec><sec id="ab-eoi250031-9"><title>Results</title><p>After propensity score matching, each cohort had 1193 patients. The mean (SD) age was 53.2 (16.1) years; 1662 were male (69.7%), 641 were female (26.9%), and for 83 patients (3.5%), the sex was unknown. At 6 months, patients with concomitant cannabis use with RD repaired by any method had a reduced risk of developing subsequent PVR (25 events [2.10%] vs 52 events [4.36%]; RR, 0.48; 95% CI, 0.30-0.77; <italic toggle="yes">P</italic>&#8201;=&#8201;.002) and requiring complex RD repair (37 [3.10%] vs 60 [5.03%]; RR, 0.62; 95% CI, 0.41-0.92; <italic toggle="yes">P</italic>&#8201;=&#8201;.02) when compared with controls. Similar results were observed at 1 year for both outcomes.</p></sec><sec id="ab-eoi250031-10"><title>Conclusions and Relevance</title><p>Patients who underwent initial repair for RD with concomitant cannabis use were less likely to develop PVR and require subsequent complex RD repair compared with matched patients without documented cannabis exposure; however, the absolute difference in rates was small. While this protective association noted with cannabis use could be due to the population using it rather than an effect of the cannabis itself, the findings suggest that cannabis use might have a role in reducing PVR development. Intervention trials would be needed to try to control for confounding factors.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>